Accuray (NASDAQ: ARAY) reported Q1 EPS of ($0.12), $0.02 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $89.6 million versus the consensus estimate of $87.76 million.

Accuray sees FY2016 EPS of $395.00-$410.00, versus the consensus of $402.28.

"We executed on our commercial strategies during the first quarter, resulting in continued momentum in order activity and improvements in overall financial performance," said Joshua H. Levine, president and chief executive officer of Accuray. "Our team focused on positioning the TomoTherapy System as a mainstream device, which led to more than 50 percent of its orders during the quarter being placed by sites with single or dual vaults. At the same time, we continued to see order momentum for the CyberKnife® M6™ with the InCise™ Multileaf Collimator as our first installation sites demonstrated its ability to provide extremely precise treatments in significantly reduced time for an expanded patient population."

For earnings history and earnings-related data on Accuray (ARAY) click here.